Although real progress has been made in managing depression over recent decades, significant hurdles remain. In fact, around ...

The EMA's human medicines committee, the CHMP, has recommended approval of Eli Lilly's oral GLP-1 agonist Foundayo for weight ...

"Treating thyroid eye disease requires balancing efficacy, safety, and the practical realities of long-term treatment," said ...

The CHMP has backed Rasonque (daraxonrasib) for adults with metastatic pancreatic adenocarcinoma who have received at least ...

August and September brought leadership changes across healthcare communications, consulting, investment, and industry ...

The list of illnesses that seem to benefit from treatment with GLP-1 agonists seems to get ever longer, and a study has ...

Reimbursement authority NICE has turned down routine NHS use of Roche's Itovebi for a specific form of breast cancer, a ...

Sanofi will not be fined for disparaging an influenza vaccine sold by rival CSL in a marketing campaign that ran in the EU, ...

Fragmented data does more than slow trials down. In some cases, it can limit eligible patients from participating in a trial ...

Roche has added to its weight-loss drug pipeline again, turning to China's Rona Therapeutics for an RNAi candidate targeting ...

GSK is preparing to cut more than 1,200 positions from its workforce in Belgium as part of a cost-saving programme launched ...

Saunders' latest spell as CEO started in 2023, as Bausch Health worked to spin Bausch + Lomb out as an independent public ...